Adicet Bio Q3 net loss $22M; ADI-001 shows 78% ORR/CR, pivotal program planned H1 2023

Adicet Bio, Inc.

2022-Q3 EPS reported -$0.98

Net loss of $22.0M ($0.53 per share) vs $14.0M in Q3 2021; R&D expenses rose to $16.6M.
Cash and cash equivalents $282.7M as of Sep 30, 2022; runway into first half of 2025.
ADI-001 Phase 1 data: 78% ORR and CR (7/9) in relapsed/refractory B-cell NHL; 100% in prior CAR-T patients.
Expects to initiate a potentially pivotal program for ADI-001 in the first half of 2023.
In-house manufacturing in Redwood City expected operational in Q4 2022; R&D webcast Nov 10, ASH update Dec 11.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Adicet Bio, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s, EPS net loss of $0.53 per basic and diluted share.

Period: the third quarter ended September 30, 2022
Net income: Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s
EPS: net loss of $0.53 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted share

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.